A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Canceropen access
- Authors
- Jo, H.[Jo, H.]; Lee, M.-S.[Lee, M.-S.]; Lee, Y.-P.[Lee, Y.-P.]; Kim, H.[Kim, H.]; Hong, J.Y.[Hong, J.Y.]; Lee, J.[Lee, J.]; Park, S.H.[Park, S.H.]; Park, J.O.[Park, J.O.]; Park, Y.S.[Park, Y.S.]; Lim, H.Y.[Lim, H.Y.]; Kang, W.K.[Kang, W.K.]; Kim, S.T.[Kim, S.T.]
- Issue Date
- Aug-2022
- Publisher
- Elsevier Ltd
- Keywords
- Aflibercept; bevacizumab; colorectal cancer; target therapy
- Citation
- Clinical Oncology, v.34, no.8, pp.E323 - E328
- Indexed
- SCIE
SCOPUS
- Journal Title
- Clinical Oncology
- Volume
- 34
- Number
- 8
- Start Page
- E323
- End Page
- E328
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/97428
- DOI
- 10.1016/j.clon.2022.02.011
- ISSN
- 0936-6555
- Abstract
- Aim: To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. Materials and methods: We analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020. This analysis included 67 patients receiving FOLFIRI plus aflibercept and 83 receiving FOLFIRI plus bevacizumab. Results: The overall response rate (ORR) was 13.6% (95% confidence interval 4.85–22.34) in the FOLFIRI–aflibercept group and 14.7% (95% confidence interval 6.68–22.71) in the FOLFIRI–bevacizumab group. This difference in ORR was not statistically significant. The median progression-free survival was 8.6 months in the FOLFIRI–bevacizumab group and 8.5 months in the FOLFIRI–aflibercept group (P = 0.752). Patients in the FOLFIRI–bevacizumab group showed a median overall survival of 12.4 months, whereas patients in the FOLFIRI–aflibercept group had a median overall survival of 13.7 months (P = 0.276). There were no significant differences in survival between the two treatment groups. The adverse events were also largely similar between the two groups. However, hypertension of grade 3 or more was more frequent in the FOLFIRI–aflibercept group. Conclusion: FOLFIRI plus bevacizumab and FOLFIRI plus aflibercept had similar anti-tumour activities and toxicity profiles when used as second-line therapy in mCRC patients. Based on these data, both aflibercept and bevacizumab are suitable anti-angiogenic agents when used in combination with FOLFIRI for mCRC. © 2022 The Author(s)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.